Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

294

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Biliary Tract Cancer

Interventions

DRUG: Volrustomig
DRUG: Bevacizumab
DRUG: Lenvatinib
DRUG: Rilvegostomig
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

AstraZeneca